1 active not recruiting, 1 suspended, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Suspended 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Vudalimab: new trials by email Literature Review of Vudalimab trials Research Report on Vudalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Terminated | Emory University | 4 | 2023-08-03 | 2025-09-15 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies vudalimab - Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Active not recruiting | Xencor, Inc. | 170 | 2022-07-21 | 2025-02-07 |
| Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer Vudalimab - Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma | Phase 2 | Suspended | Northwestern University | 54 | 2022-07-21 | 2026-08-14 |
Prostatic Neoplasms (2) · Adenocarcinoma, Clear Cell (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Thyroid Carcinoma, Anaplastic (1) · Uterine Cervical Neoplasms (1)
Emory University (1) · Northwestern University (1) · Xencor, Inc. (1)
United States (3)
Bassel Nazha, MD, MPH (1) · Jochen H Lorch, M.D. (1) · Jolene Shorr (1)
P30CA060553 (1), P30CA138292 (1)